Cite
HARVARD Citation
Facon, T. et al. (2021). Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet oncology. 22 (11), pp. 1582-1596. [Online].